Extended-Duration Therapy in Advanced Non-Small-Cell Lung Cancer: Promise and Pitfalls

被引:1
|
作者
Levy, Benjamin [1 ]
Drilon, Alexander [1 ]
Siu, KarLeung [1 ]
Grossbard, Michael [1 ]
机构
[1] Beth Israel Hosp, New York, NY 10003 USA
关键词
Carboplatin; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Navelbine; Lomustine; Paclitaxel; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; SUPPORTIVE CARE; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; GEFITINIB; BEVACIZUMAB;
D O I
10.3816/CLC.2010.n.050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For many years, the cornerstone of treatment for non small-cell lung cancer (NSCLC) has been third-generation platinum-based chemotherapy. Unfortunately, clinical outcomes with the use of this approach have remained poor, with median survival times of only 8-13 months. In an attempt to improve survival, several therapeutic strategies have recently been investigated, including extended-duration chemotherapy. Although historically maintenance chemotherapy in NSCLC has resulted in less-than-optimal outcomes and there has been a recent surge in interest with this treatment modality. This has been in part because of the strategy of the early delivery of a non cross-resistant agent after platinum chemotherapy, now termed switch maintenance therapy. Results from several recent phase III trials using this strategy are shifting the treatment paradigm of patients with advanced-stage NSCLC. Despite more favorable outcomes demonstrated with this strategy, study designs and reported results have not been without critique. Here, we review all published extended-duration chemotherapy strategies in NSCLC and seek to clarify outstanding issues as they relate to more recent approaches using this strategy.
引用
收藏
页码:383 / 390
页数:8
相关论文
共 50 条
  • [1] The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials
    Clarey, J.
    Kao, S. C.
    Clarke, S. J.
    Vardy, J.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1229 - 1233
  • [2] Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?
    Sibille, Anne
    Wauters, Isabelle
    Vansteenkiste, Johan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 529 - 539
  • [3] Maintenance Therapy in Advanced Non-small Cell Lung Cancer
    Coate, Linda E.
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : 723 - 734
  • [4] Treatment of advanced non-small-cell lung cancer in the elderly
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Marianna Luciana
    Castaldo, Vincenzo
    Palazzolo, Giovanni
    Mazzeo, Nicole
    LUNG CANCER, 2009, 66 (03) : 282 - 286
  • [5] Strategies for Prolonged Therapy in Patients With Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos
    Novello, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5116 - 5123
  • [6] Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue
    Petrelli, Fausto
    Ghilardi, Mara
    Cremonesi, Marco
    Cabiddu, Mary
    Barni, Sandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1455 - 1465
  • [7] Maintenance chemotherapy for non-small-cell lung cancer
    Kim, Young Hak
    Mishima, Michiaki
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 505 - 510
  • [8] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [9] Current and emerging therapies for patients with advanced non-small-cell lung cancer
    Sheth, Sheetal
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (01) : S9 - S14
  • [10] Maintenance Therapy for Advanced Non-Small-Cell Lung Cancer A Pilot Study on Patients' Perceptions
    Peeters, Lies
    Sibille, Anne
    Anrys, Bea
    Oyen, Christel
    Dooms, Christophe
    Nackaerts, Kristiaan
    Wauters, Isabelle
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (08) : 1291 - 1295